Fig. 7
RBX1 depletion sensitized 17ploss prostate cancer cells to POLR2A inhibition. a Protein levels of POLR2A, p53, Rbx1, and β-Actin in human prostate cancer cell lines. b, c Cell proliferation of 17pneutral (22Rv1 and DU145) and 17ploss cells (PC3 and VCaP) treated with α-amanitin (b) or actinomycin D (c). d, e RBX1 depletion sensitizes the 17ploss DU145 cells to the treatment of the POLR2A inhibitor, α-amanitin. Representative images (d) and quantitative results (e) of cell survival are shown. f Cell proliferation of human prostate cancer cell lines under α-amanitin treatment. 17pneutral (22Rv1 and DU145) and 17ploss (PC3 and VCaP) cells, with or without Dox-induced RBX1 knockdown, were treated with increasing doses of α-amanitin. Data are representative of three independent experiments
